BioCentury | Apr 28, 2020

Merck’s adjusted revenue guidance shows product mix matters during COVID-19

Merck’s heavy reliance on hospital-administered products, vaccines and animal health has left it more exposed than its pharma peers to the commercial impacts of the COVID-19 pandemic. The company cut its 2020 revenue guidance by...
BioCentury | Feb 6, 2020

Beyond Keytruda: How Merck envisions innovation and growth after a spinout

As Merck becomes the latest large pharma to split in two, separating its key growth drivers and innovative programs from its slower-growing businesses, the slimmed-down innovative company will rely on the fruits of recent and...
BioCentury | Jan 2, 2020
Politics & Policy

Drug price hikes would have been impossible under pending bipartisan legislation backed by White House, Democrats

The latest round of increases in the list prices of drugs highlights how pending bipartisan legislation could force biopharma companies to rethink their business models. In what has become a predictable biannual event, manufacturers announced...
BioCentury | Nov 16, 2019
Company News

Nov. 15 Company Quick Takes: Qiagen continues climb after confirming takeout offers; plus Fetroja, selumetinib, PharmAbcine, semaglutide

Qiagen confirms acquisition interest Qiagen N.V. (NYSE:QGEN; Xetra:QIA) said Friday it is reviewing its strategic alternatives after receiving several “non-binding indications of interest for the acquisition” of the diagnostics company. Since acquisition rumors emerged Wednesday,...
BioCentury | Nov 13, 2019
Product Development

Hua Phase III diabetes data make good on glucokinase but disappoint investors

Hua’s announcement that glucokinase activator dorzagliatin met its endpoints in a Phase III diabetes study marks a watershed moment for a target whose disease-modifying potential was long stymied by the limitations of previous compounds. Yet...
BioCentury | Sep 25, 2019
Company News

Sept. 24 Company Quick Takes: FDA approves smallpox vaccine; plus Epidyolex, Vitrakvi, Oral semaglutide, Takeda-Evotec, Guerbet-IBM Watson

FDA approves Bavarian Nordic’s smallpox/monkeypox vaccine FDA approved Jynneos MVA-BN from Bavarian Nordic A/S (CSE:BAVA; Pink:BVNRY) to prevent smallpox and monkeypox, making the vaccine the only approved non-replicating smallpox vaccine in the U.S. and the...
BioCentury | Jun 20, 2019
Company News

Beyond Keytruda: Merck details plans for future growth

Merck is looking beyond its blockbuster cancer drug Keytruda pembrolizumab to late-stage programs in infectious disease, vaccines and chronic indications to help the pharma weather any revenue shortcomings when its diabetes drug Januvia sitagliptin comes...
BioCentury | Feb 8, 2019
Clinical News

Hua starts U.S. Phase I trial of diabetes candidate

Hua Medicine Ltd. (HKEX:2552) began a Phase I trial of its dorzagliatin (sinogliatin, HMS5552, RO5305552) in combination with Januvia sitagliptin in patients with Type II diabetes. The open-label, U.S. trial will evaluate the pharmacokinetic and...
BioCentury | Sep 21, 2018
Politics, Policy & Law

Filling the rebate void

HHS’s proposal to eliminate drug rebates should have the intended consequence of increasing transparency into drug pricing in the short term. But the long view is that value-based pricing or alternative co-pay agreements will do...
BioCentury | Jun 22, 2018
Clinical News

Novo's oral GLP-1 analog meets primary in Phase IIIa trials compared with approved therapies

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) reported that oral diabetes candidate semaglutide was at least non-inferior to two approved therapies in reducing HbA1c and led to greater body weight reductions than both drugs in a...
Items per page:
1 - 10 of 345